Form 4: Ultragenyx CEO Emil Kakkis Sells Shares in Open Market Transaction

Ultragenyx CEO Emil Kakkis sold 11,727 shares of common stock at an average price of $42.23 on December 30, 2024.

Summary

• Emil Kakkis, the President and CEO of Ultragenyx Pharmaceutical Inc., sold 11,727 shares of common stock on December 30, 2024.
• The shares were sold at a weighted average price of $42.23, with individual transaction prices ranging from $41.58 to $43.02.
• Following the transaction, Mr. Kakkis directly owns 564,605 shares and indirectly owns 2,183,985 shares through the Emil Kakkis and Jenny Soriano Living Trust.
• The indirect holdings include shares underlying restricted stock units (RSUs) that are subject to vesting conditions.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing a stock sale by an executive. It is neutral in sentiment and does not indicate any positive or negative implications for the company's performance.

Industry Context

This is a routine Form 4 filing, which is common for executives who trade shares in their own company. It provides transparency into insider transactions.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and this filing is consistent with those requirements.
• The sale of shares by a CEO is not unusual, and the size of the transaction is not significant relative to the total shares owned by Mr. Kakkis.

Stakeholder Impact

• The stock sale by the CEO may have a minor impact on shareholder sentiment, but it is unlikely to have a significant effect on the company's operations or financial performance.

Key Dates

Keywords

Ultragenyx, Emil Kakkis, stock sale, insider trading, Form 4, RARE, executive, share transaction